MTSS1 may thus play a wider role in the response to drugs with the potential to eliminate malignant cells, which may be of relevance not only for the application of targeted therapy in AML, but also for other tumor entities in which downregulation of MTSS1 plays a role [18–22, 44]. The gene discussed is MTSS1; the disease is acute myeloid leukemia.